William E. Carson
Immunology and Microbiology · The Ohio State University
Publications
687
Citations
20,985
Est. group size
~68
Recurring co-author estimate
Active years
57
Publishing since 1970
William E. Carson's research centers on cancer immunotherapy, particularly the use of cytokines like interleukin-12, interleukin-15, and interferon to boost the immune system's ability to fight cancers such as melanoma and neuroendocrine tumors. His work includes clinical trials testing these immune-based treatments, often in combination with other therapies, alongside laboratory studies of immune cell behavior in cancer. The publication record also includes a diverse set of collaborative studies outside this core focus, spanning areas like sleep therapy in cancer patients, brain imaging, and computational methods.
Publication output was relatively steady at 16-33 papers per year from 2017-2022, then increased sharply starting in 2023, likely reflecting a surge in trial-related outputs and collaborative datasets.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance)
Cancer Immunology Research · 2026
- Abstract 7628: Sensitive detection of microRNAs from human melanoma cell lines and FFPE tissue using fluorescent nitrogen-vacancy center nanodiamonds
Cancer Research · 2026
- Data from Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance)
2026
- Table S1 from Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance)
2026
- Table S2 from Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance)
2026
- Figure S2 from Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance)
2026
- Figure S1 from Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance)
2026
- Combined Treatment With Cognitive Behavioral Therapy for Insomnia and Acceptance and Commitment Therapy Enhances Objective and Subjective Reports of Sleep in Patients With Advanced Cancer
Psycho-Oncology · 2025
- Model selection to achieve reproducible associations between resting state EEG features and autism
Scientific Reports · 2024
- A widespread electrical brain network encodes anxiety in health and depressive states
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- A phase II randomized control trial of triapine plus lutetium 177 DOTATATE versus lutetium 177 DOTATATE alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors.
Journal of Clinical Oncology · 2024
- Abstract 1012: Colorectal cancer in the American Indian and Alaska Native community: A holistic review
Cancer Research · 2024
- Data from Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy
2023
- Variant Sciatic Nerve Anatomy in Relation to the Piriformis Muscle on Magnetic Resonance Neurography: A Potential Etiology for Extraspinal Sciatica
Tomography · 2023
- Related Article from Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy
2023
- Cancer Research×23
- Journal of Clinical Oncology×20
- Annals of Surgical Oncology×7
- Scientific Reports×6
- Cancer Immunology Immunotherapy×6
- Lukman O. Afolabi
Immunology and Microbiology · Indiana University
- Maria Velegraki
Immunology and Microbiology · The Ohio State University
- Sandro Matosevic
Immunology and Microbiology · Purdue University West Lafayette
- Bethany L. Mundy-Bosse
Immunology and Microbiology · The Ohio State University
- Kyle B. Lupo
Immunology and Microbiology · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile